A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease | Zendy

Shashikant Srivastava | Zendy; Devyani Deshpande | Zendy; Carleton M. Sherman | Zendy; Tawanda Gumbo | Zendy

Open Access

A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease

Author(s) -

Shashikant Srivastava,

Devyani Deshpande,

Carleton M. Sherman,

Tawanda Gumbo

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx308

Subject(s) - moxifloxacin , mycobacterium avium complex , regimen , medicine , mycobacterium avium intracellulare infection , microbiology and biotechnology , antibacterial agent , antibiotics , mycobacterium , biology , tuberculosis , pathology

To develop a thioridazine/moxifloxacin-based combination regimen for treatment of pulmonary infection due to Mycobacterium avium-intracellulare complex (MAC) that kills bacteria faster than the standard treatment regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research